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Abstract: Protein microarrays are powerful tools that are widely used in systems biology 
research.  For  infectious  diseases,  proteome  microarrays  assembled  from  proteins  of 
pathogens will play  an  increasingly important role in  discovery of diagnostic markers, 
vaccines, and therapeutics. Distinct formats of protein microarrays have been developed for 
different applications, including abundance-based and function-based methods. Depending 
on the application, design issues should be considered, such as the need for multiplexing 
and  label  or  label  free  detection  methods.  New  developments,  challenges,  and  future 
demands in infectious disease research will impact the application of protein microarrays 
for discovery and validation of biomarkers. 
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1. Introduction  
Large-scale genome sequencing projects first advanced knowledge of the theoretical composition of 
proteomes and led to the development of DNA microarrays for studying gene transcription at the 
organism-scale.  Using  genome  sequence  data  to  guide  the  direct  examination  of  proteomes  then 
enabled the study of host-pathogen interactions occurring beyond the level of gene transcription. It 
soon became evident that direct correlations between gene expression and protein abundance were rare 
[1,2], driving the development of new approaches to study complex proteomes. Protein microarrays 
are  ideally  suited  to  serve  this  purpose  and  have  enormous  potential  applications  in  biomarker 
discovery, diagnosis, vaccine development, and drug discovery for infectious diseases. Fluorescence-
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based  detection  of  protein  interactions  is  similar  to  gene  array  methods,  and  data  analysis  often 
employs  approaches  previously  developed  for  genome  and  transcription  studies.  The  number  of 
proteins that can be printed on a single microarray surface also approaches the same upper limits as 
nucleic-acid based systems. Multiplexing of fluorescent probes is limited by the ability to separate 
signals  of  overlapping  emission  spectra.  Generally,  pair-wise  comparisons  of  2–3  differentially 
labeled, experimental and control samples can be analyzed. For example, serum IgG and IgM binding 
to arrayed proteins can be independently probed by fluorescently labeled secondary antibodies, and 
detected by a confocal laser scanner (such as Genepix, Molecular Devices, Sunnyvale, CA, USA). A 
complete high-throughput  screening of thousands  of interactions  can be performed accurately  and 
rapidly (Figure 1). Direct labeling of probes may also be used, though structure and function may be 
adversely affected. Most label-free techniques [3] provide real-time measurements and in some cases 
yield  kinetics  (Figure  1),  providing  further  insight  into  molecular  interactions.  Surface  plasmon 
resonance (SPR) [4], nanowire surfaces [5], and mass spectrometry [6] are examples of label-free 
methods  that  are  applied  in  the  field  of  protein  microarrays.  Of  these,  only  a  limited  number  of  
SPR-based  instruments  are  currently  available  for  analysis  of  complex  protein  microarrays.  SPR 
imaging (SPRi) is a more recent and promising development [3,7]. While planar arrays that use slides 
or  chips  for  immobilizing  capture  molecules  are  most  common,  suspension  arrays  based  on 
microbeads  have  many  important  applications.  The  xMAP  technology  developed  by  Luminex 
Corporation (Austin, TX, USA) uses 5.6 micrometer polymer beads infused with two fluorescent dyes 
at different ratios to yield up to 100 distinct bead sets. The binding measurements are performed by 
flow cytometry with two lasers, one for the identification of the bead and the other for the sample. 
Bead-based arrays are very useful for standardizing assays, with an upper limit of 80 independent 
immobilized probes. 
Figure 1. Measuring probe interactions with microarrayed proteins. Top: Detecting 
binding events using a fluorescently-labeled secondary probe, such as an antibody, and the 
resulting laser-scanned image. Bottom: Label-free interactions detected by surface plasmon 
resonance, resulting in a sensorgram of binding kinetics. 
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Protein microarrays are increasingly used in infectious disease research to identify new biomarkers 
that are involved in the disease process or that are targets of immune responses [8–13]. In contrast with 
other proteomic techniques such as 2-D gel electrophoresis and mass spectrometry, the arrayed probes 
are known, conforming easily to high-throughput applications that require examination of the entire 
proteome of an infectious agent. A variety of formats have been developed for the study of pathogen 
proteomes.  Capture  and  reverse-phase  are  examples  of  abundance-based  microarrays  produced  by 
spotting either antibodies [10] or antigens [14] on a substrate. The arrays can be probed with serum, 
plasma,  and  other  biological  samples  to  detect  binding  interactions.  Microarrays  based  on  well-
characterized  antibodies  are  specifically  useful  for  identifying  biomarkers  and  quantification  of 
proteins. Aptamers [15], affibodies [16], or engineered antibody fragments [17] are alternative capture 
molecules. Antigen arrays find applications in serodiagnosis of disease, antibody-response profiling, 
and evaluation of immunity after vaccination. In reverse-phase protein microarrays (RPPMs), small 
amounts of biological samples from cells, tissues, sera, or plasmas are directly printed on the slide 
[18,19]. These arrays are probed with a single protein of interest that is detected by labeled antibodies. 
RPPMs  were  successfully  used  for  the  screening  of  cell-signaling  pathways  and  posttranslational 
modifications  of  proteins  [20–22].  The  biochemical  activities  of  arrayed  proteins  have  also  been 
analyzed [23] by enzyme activity or substrate activity, and protein interaction with other proteins, 
nucleic acids, or drugs [24–26].  
2. Proteome Microarrays and Host Antibody Responses 
The  host  antibody  response  provides  a  signature  of  pathogen  proteins  displayed  by  infectious 
diseases that can be captured and detected by microarrays. Our studies with vaccinia virus [12] and the  
bacterium Yersinia pestis [11] exemplify the application of antigen microarrays for the analysis of 
immune responses (Figure 2). Vaccinia is a large DNA virus (Orthopoxviridae) that replicates in the 
cytoplasm  of  host  cells  from  genomes  encoding  150–300  proteins.  The  virion  is  comprised  of 
approximately 100 proteins. Most phenotypic variability occurs in proteins encoded in the terminal 
regions of the genome that are associated with  host  virulence or immune evasion. Some of these 
terminal-region proteins are secreted during cell infection and interfere with host immunity by binding 
complement  factors,  cytokines,  and  chemokines,  while  others  interfere  with  signaling  pathways 
regulating host gene expression and apoptosis. To construct a proteome microarray, genomic DNA of 
the  Copenhagen  (NC_001559.1)  vaccine  strain  (Dryvax)  was  used  as  the  template  for  PCR 
amplification of the 273 open reading frames (ORF). Gateway recombination cloning (Invitrogen, 
Carlsbad, CA, USA) was employed to facilitate high-throughput production of proteins from all ORF 
clones. All DNA clones were sequence-verified through the entire length of their inserts. Baculovirus-
based expression was used to produce the recombinant viral proteins as GST-tagged fusions to ensure 
high yield of properly folded proteins with posttranslational modifications that are similar to those 
encountered in the human host. The GST-tagged proteins from cell lysates were affinity purified to 
90% homogeneity in a single step by using glutathione-agarose in 96-well plates and analyzed for 
correct size and abundance by Western blots. Virus and control proteins were printed onto glass slides 
coated with a thin layer of nitrocellulose. Ultimately, 95% of the proteome was successfully expressed, 
purified, and arrayed.  Int. J. Mol. Sci. 2010, 11                       
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Figure  2.  Pathogen  proteome  microarrays. Confocal laser scanner image of proteins 
spotted in duplicate onto microarray slides, visualized using a rabbit anti-GST antibody 
bound to Cy5-labeled anti-rabbit antibody. (a) Vaccinia virus; (b) Yersinia pestis. 
a             b 
     
 
A  standard  assay  for  measuring  antibody  interactions  with  proteins  of  the  vaccinia  proteome 
microarray was first developed with a pool of therapeutic human sera collected from vaccinia-immune 
individuals (VIg) and this data was compared to results obtained from individuals vaccinated against 
smallpox using Dryvax. The  assay  consisted of incubating a dilution of serum on the microarray 
surface, washes, and finally detection with a fluorescently labeled anti-Ig antibody. Fluorescent images 
were captured by scanning with a confocal laser (GenePix 4000B; Molecular Devices). Because only a 
very small sample volume (1–2 L) is required, this approach is ideal for limiting the amount of 
sample consumed, often necessary with clinical material. A high level of reproducibility with a very 
low background was apparent in repetitive assays that confirmed previously reported antigens and 
identified  new  proteins  that  may  be  important  for  neutralizing  viral  infection.  Incubation  of  the 
microarray  with  VIg  identified  nine  proteins  that  consistently  bound  antibody,  while  antibody 
interactions  with  all  other  proteins  were  insignificant,  requiring  no  further  treatment  to  suppress  
non-specific  signals.  These  antigens  were  also  recognized  by  antibodies  from  individual  subjects 
following primary smallpox vaccination and were diverse in function, consisting of regulatory, surface, 
core,  and  secreted  proteins.  The  identical  vaccinia  proteins  clustered  into  proteins  recognized  by 
primary and secondary vaccinated subjects based solely on signal intensities. The vaccinia proteins 
C3L  and  I1L  were  not  previously  reported  as  antibody-recognized  antigens.  The  nine  antigenic 
proteins we identified did not bind antibody from non-vaccinated sera, confirming the specificity of 
these antibody-antigen interactions. However, O2L and H7R were reactive with antibodies from both 
VIg  and  non-vaccinated  control  sera,  suggesting  that  these  were  cross-reactive  or  non-specific 
interactions. These results indicated that only a small subset of proteins present within the complex 
orthopoxvirus proteome was associated with antibody responses. In addition, the human response to 
individual  proteins  was  variable  as  sera  from  more  than  half  of  the  subjects  contained  IgG  that 
recognized  >4 vaccinia  proteins,  while  the  remaining  samples  recognized  one  to  three  proteins. 
Further, antibodies from most individuals recognized a greater number of viral proteins after a boost Int. J. Mol. Sci. 2010, 11                       
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vaccination  compared to  a single vaccination, suggesting that repeated infection expands  the total 
number of proteins recognized by IgG. A previous report [27] similar to our study on vaccinia [12], 
analyzed the serological response to vaccinia and smallpox, observing that a significant amount of the 
antibody  response  to  vaccinia  was  not  involved  in  the  virus  neutralization,  but  could  be  used  as 
potential markers for diagnostic and vaccine development. A later report [28] evaluated an attenuated 
smallpox  modified  vaccinia  virus  Ankara  (MVA)  an  alternative  to  Dryvax  vaccine  by  comparing 
antibody profiles  in  the sera of humans  and monkeys. The overall immunogenicity of MVA  was 
reported to be comparable to that of the Dryvax vaccine and the study concluded that MVA may be a 
useful alternative to Dryvax. 
Our vaccinia virus microarray was expanded to allow analysis of additional poxviruses. Monkeypox 
is a zoonotic viral disease that occurs primarily in Central and West Africa. Immunity to monkeypox is 
provided by vaccination against smallpox caused by the closely related variola virus. To differentiate 
antibody responses to monkeypox virus infection from human smallpox vaccination, we developed a 
protein microarray covering 92–95% (166–192 proteins) of representative proteomes from monkeypox 
viral clades of Central and West Africa, including 92% coverage (250 proteins) of the vaccinia virus 
proteome as a reference orthopox vaccine. Serum IgG of cynomolgus macaques that recovered from 
monkeypox recognized at least 23 separate proteins within the orthopox meta-proteome, while only 14 
of these proteins were recognized by IgG from vaccinated humans. There were 12 of 14 antigens 
detected by sera of human vaccinees that were also recognized by IgG from convalescent macaques. 
The greatest level of IgG binding for macaques occurred with the structural proteins F13L and A33R, 
and the membrane scaffold protein D13L. Significant IgM responses directed towards B16R, F13L, 
and A33R of monkeypox virus were detected before onset of clinical symptoms in macaques. Results 
from this study suggested that antibodies from vaccination recognized a small number of proteins 
shared with pathogenic viral strains, while recovery from infection also involved humoral immunity to 
antigens uniquely recognized within the monkeypox virus proteome (unpublished data). 
To  identify  antibody  biomarkers  that  could  distinguish  plague  from  infections  caused  by  other 
bacterial pathogens [11], we developed a microarray comprised of the proteome from the bacterium 
Yersinia pestis. The chromosome of Y. pestis CO92 encodes approximately 3885 proteins, while an 
additional 181 are episomally expressed by pCD1, pMT1, and pPCP1. For comparison, the proteome 
of Y. pestis KIM contains 4202 individual proteins, 87% in common with CO92,  and the closely 
related enteric pathogen Y. pseudotuberculosis contains approximately 4038 proteins (chromosome 
plus  plasmids).  The  microarray  was  comprised  of  proteins  representative  of  over  75%  of  the 
4066 ORFs present within the Y. pestis genome. In a manner similar to the vaccinia microarray, the  
Y. pestis proteins were produced as full-length polypeptides fused to GST as an affinity isolation tag. 
An  in  vitro  translation  method,  based  on  E.  coli  lysates,  was  used  to  express  the  proteins  in  a  
gram-negative background. The ORF clones were fully sequenced to confirm quality and identity. The 
affinity-purified proteins were characterized by SDS gels and Western blots probed with an anti-GST 
antibody.  Different  approaches  for  studying  the  antibody  repertoire  for  plague  in  rabbits  and  
non-human  primates  were  investigated.  Based  on  results  from  experiments  using  the  Y.  pestis 
proteome microarray, we identified new candidates for antibody biomarkers of bacterial infections and 
patterns  of  cross-reactivity  with  a  panel  of  other  gram-negative  pathogens  [11]. We  were  able  to 
cluster  the  proteins  recognized  by  the  antibodies  into  three  groups:  common  proteins  of  all  Int. J. Mol. Sci. 2010, 11                       
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gram-negative bacteria, combinations of proteins unique to one pathogen, and proteins unique to one 
pathogen. This example demonstrates the power of a high-density proteome microarray to dissect the 
complex immunological relationships among a group of related human pathogens. Convalescence sera 
from vaccinated non-human primates that survived an otherwise lethal aerosol challenge with Y. pestis 
CO92 (plague) or Bacillus anthracis Ames spores (anthrax) were also examined. In addition to the 
CaF1 and LcrV proteins comprising the vaccine components, a subset of proteins from the Y. pestis 
proteome were recognized by antibodies from plague survivors and none of these were detected with 
antibodies  from  anthrax  survivors  or  non-challenged  controls.  Signature  patterns  of  antibody 
recognition  were  identified  that  reflected  the  orthologous  relationships  among  proteomes  of  these 
bacteria.  A  high  degree  of  cross-reactivity  in  the  antibody  response  to  Burkholderia  and  related 
bacteria was also previously reported [29]. Further, a protein microarray consisting of 4% of Y. pestis 
proteins was used by Li et al. to profile antibody responses to live plague vaccine in rabbits [30], 
sentinel animals [31], and plague patients [32]. Predominant responses were observed for 11 proteins 
in addition to F1 and V antigens in rabbits. In plague patients, they identified 14 proteins that were 
potential serodiagnostic biomarker candidates and found antibody responses from different plague foci 
responsible for different clinical symptoms. 
Additional  microarray  studies  of  antibody  responses  to  bacterial  pathogens  were  reported. 
Sundaresh  et  al.  [33]  developed  a  protein  microarray  with  244  of  the  most  reactive  Francisella 
tularensis proteins derived from a larger chip. In this study, they identified a set of immunodominant 
antigens from F. tularensis patients suitable for diagnosis development. In another study [34], a similar 
protein microarray approach was employed to find immunodominant antigens in mice vaccinated with 
killed  F.  tularensis  vaccine  and  challenged  with  a  virulent  F.  tularensis  strain.  The  study  found 
31 antigens in addition to 12 known immunodominant antigens of F. tularensis discovered by other 
methods. This was also the first published report to use protein microarrays for studying protective 
immune responses to an infectious agent. Immunoreactive antigens of Coxiella burnetti, the causative 
agent of Q fever, were identified using a protein microarray consisting of 75% of the  C. burnetti 
proteome assembled by using a cell free protein expression system [35]. Serum from Q fever patients 
and individuals vaccinated with Q-Vax vaccine strongly reacted to 50 antigens of C. burnetti that were 
confirmed by ELISA including antigens isolated from an E. coli expression system. In yet another 
study, human and goat antibody responses to Brucella melitensis infection were analyzed [36], finding 
that there was differential recognition of antigens by the two host species. The serodiagnostic proteins 
were of potential value for diagnostic purposes as brucellosis is diagnosed by measuring the antibodies 
to lipopolysaccharide (LPS), which cannot distinguish between past and present infection in endemic 
areas. Antibody response to Lyme borreliosis disease in humans and mice was studied by Barbour et 
al. [37], using a protein microarray comprising 80% of the proteins from  Borrelia burgdorferi. A 
comprehensive analysis of the sera from B. burgdorferi patients and rodents revealed that only a small 
set of antigens elicited antibody responses in both hosts, while the majority of B. burgdorferi proteins 
did not induce antibodies. It is also possible to focus on specific subsets of antigens identified by 
bioinformatics.  For  example,  a  protein  array  produced  from  the  outer  membrane  proteins  of 
Pseudomonas aeruginosa was constructed [38] to study the immune response in patients, and several 
antibody-binding antigens were identified by this group as potential diagnostic markers. In another Int. J. Mol. Sci. 2010, 11                       
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example,  a  recombinant  Niesseria  meningitidis  protein  array  was  used  for  screening  serum  from 
meningitis patients [39] for immune responses to phase-variable expressed proteins.  
3. Protein-Protein Interactions (Non-Antibody) 
The development of new proteomics methods has been driven in part by the need to identify new 
types  of  infection  biomarkers.  Though  studies  of  antibody  responses  dominate  the  field,  protein 
microarrays  should  be  considered  as  an  alternative  approach  to  examine  other  catagories  of  
host-pathogen interactions. Research areas with well-established cell proteomics data are prime targets. 
For example, because many of the host factors associated with phagosomes have been identified [40], 
protein microarrays may provide a convenient model system to examine interactions with pathogen 
proteomes associated with this portal of entry. In a similar manner, targeted microarrays comprised of 
pathogen proteins may be used to examine host interactions. The few published examples from this 
developing field of study should be mentioned. In one report, RPPM along with other techniques [41] 
were used to examine phosphoprotein signaling pathway in primary human small airway epithelial 
cells infected with Bacillus anthracis, identifying reduced AKT (protein kinase B) phosphorylation as 
a contributor to increased bacterial survival and pathogenicity. In another study [42], proteins from 
Group A and B streptococci were arrayed on a chip and probed with human fibronectin, fibrinogen, 
and C4 binding protein, all well-known targets of gram-positive bacteria.  
4. Alternative Methods  
The  use  of  purified  and  well-characterized  proteins  to  assemble  the  microarray  will  insure  the 
highest quality and most reproducible results. However, the high level of quality control required to 
sequence, purify, and characterize elements of a proteome microarray in the examples we described 
may  not  be  as  important  for  provisional  screening  purposes.  A  coupled  transcription/translation 
reaction was previously reported as a rapid method to develop protein microarrays against a number of 
infectious  organisms  [43,44],  bypassing  sequencing  and  purification  steps.  In  this  technique,  both 
transcription  and  translation  occur  simultaneously  to  synthesize  proteins  in  parallel  from  PCR 
products, directly on the chip. Presumably, results obtained by these methods will require follow-up 
studies with more rigorous controls for confirmation. The protein in situ array (PISA) developed by He 
and  Taussig  [45]  first  produces  DNA  constructs  from  a  PCR  of the  protein  of  interest  and  a  T7 
promoter for translational initiation followed by immobilization using a N or C terminal tag sequence. 
Another approach [25,46] called nucleic acid programmable protein array (NAPPA) included slides 
coated with avidin to capture biotinylated plasmid DNA for synthesizing proteins. Proteins with fused 
tags were synthesized and immobilized on the chips coated with molecules to bind the tags [25]. He et 
al. [47] described a technique called DNA array to protein array (DAPA) where they utilized a single 
DNA array to  make multiple copies of the same protein array.  In one example, a self-assembled 
NAPPA-based on a cell-free expression system was used for constructing a protein microarray of all 
69 proteins produced by varicella zoster virus (VZV), the cause of chickenpox [48]. Three sets of 
antigens in the VZV proteome were identified from human sera that may be useful in defining the 
clinical status of the infection and diagnostics. Another VZV protein array produced from an E. coli 
expression  system  was  later  used  to  detect  antibodies  in  human  sera  reactive  to  VZV  viral  Int. J. Mol. Sci. 2010, 11                       
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proteins  [49].  The  ORF68  (gE)  antigen  identified  in  the  study  showed  high-confidence  for 
determination of the serological response to VZV.  
Although these alternative  in  situ synthesis  methods  are rapid,  they are not  without significant 
shortcomings. It is difficult to characterize proteins expressed on the chip in contrast to direct spotting 
of purified proteins. Two studies investigated the antibody response to VZV by protein arrays made 
from either NAPPA cell-free expression system [48] or E. coli expression system [49]. Antibodies 
from the sera of patients recognized three microarrayed VZV proteins produced recombinantly with  
E. coli, whereas these identical proteins were not recognized on a NAPPA protein expression-based 
protein microarray. Interestingly, these proteins were abundantly expressed in the NAPPA protein 
microarrays, suggesting that they did not fold correctly to expose their linear epitopes for binding. 
Despite these limitations, microarrays based on in situ synthesis offer simplicity, efficiency, and high-
throughput capabilities. 
The relatively small proteomes of most viruses increase in diversity by considering variations in 
clinical isolates. For example, while human papilloma virus produces only a few proteins, sequences 
for these may diverge in the more than 100 strains of the virus. A protein microarray developed with 
13 human papilloma virus types [50] was used to examine patient sera compared to asymptomatic 
subjects. The study identified E7 proteins as the most reactive antigens in the patient group. However, 
the E7 proteins were not useful as a diagnostic biomarker because the differences between patients and 
asymptomatic  subjects  were  not  significant.  In  another  report,  a  bead  suspension  multiplex  array 
(Luminex xMAP) was used to study serological responses to 27 antigens of human papilloma virus 
[51]. The data correlated well with ELISA results and in addition the bead array was able to measure 
weak antibody responses. A protein array constructed from six coronaviruses including severe acute 
respiratory syndrome (SARS) was used for screening serum samples for virus-specific antibodies [52]. 
The microarray data predicted SARS infection in 90% of the patients  correctly with  a specificity  
of 93%.  
5. Peptide and Protein Domain Microarrays 
The high efficiency, low cost, and high-throughput nature of chemically synthesized peptides are 
significant  advantages  compared  to  production  of  recombinant  polypeptides.  Therefore,  peptide 
microarrays have been explored as another alternative to recombinant proteins, with a limited degree 
of success. A chemically synthesized peptide microarray representing the major antigens of hepatitis B 
and C viruses, human immunodeficiency virus, Epstein-Barr virus, and syphilis was constructed on a 
glass slide and antibody responses were simultaneously detected [53]. The assay showed very high 
sensitivity and specificity for the diagnostic identification of these viruses. Another proof of principle 
study [54] was reported to identify diagnostically relevant peptides using a peptide array deduced from 
bioinformatics data for Echinococcus granulosa (tapeworm) infection, achieving only 57% sensitivity 
and 94% specificity compared to ELISA.  
As an alternative to full-length polypeptides, expression and purification of protein domains may 
improve yield of stable products for use in microarrays. In one reported study, a total of 212 protein 
domains (SH3, SH2, PDZ etc.) were immobilized on nitrocellulose and screened with peptides [55]. 
The results proved that the immobilized domains were stable and could be used for binding studies. Int. J. Mol. Sci. 2010, 11                       
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Kaushansky  et  al.  [56]  constructed  an  array  based  on  protein  interaction  domains  such  as  Src 
homology, phosphotyrosine binding domains, and mouse PDZ domains produced from recombinant  
E. coli. These arrays required low sample consumption and may reduce false positive rates. Advanced 
knowledge of the specific recognition events will be required to substitute peptides or single protein 
domains for full-length proteins to ensure that important epitopes are not missed for the purpose of 
studying antibody interactions.  
6. Quality Control 
Protein stability is an important and particularly challenging factor in using protein microarrays. 
The high-throughput  nature of construction tends to  sacrifice detailed knowledge about  individual 
proteins. There are few methods available to assess folding and functionality of all arrayed proteins 
immediately before use. Recombinant proteins constructed with fusion tags to facilitate folding during 
translation offer a partial solution, especially if proper folding of the fusion protein can be readily 
assessed.  For  example,  unfolded  glutathione-S-transferase  (GST)  will  not  bind  to  glutathione,  the 
tripeptide ligand of GST, hence purification schemes employing GST fusions will favor proteins with 
stable  structures.  Fusion  tags  also  provide  a  convenient  marker  for  monitoring  quality  control  of 
protein spotting (Figure 2). However, the fusion tag may hinder protein accessibility or alter function 
in  other  ways.  Because  proteins  may  denature  during  printing  and  storage,  enzymes  or  other 
denaturing-sensitive proteins that can be assessed after printing should be included in the microarray.  
7. Antibody Microarrays 
Antibodies are a natural choice to be used as capture molecules due to their specificity, affinity, 
ease of production, and potential for engineering. For probe development, the analysis of antibody 
specificity  and  cross-reactivity  [57–59]  can  be  simplified  by  screening  against  target  or  off-target 
proteins printed as microarrays. Antibody arrays are routinely used in the field of biomarker discovery 
and validation. The detection of binding molecules to an antibody array is usually done by direct 
labeling of proteins in the sample (serum, cell, or tissue) or by a sandwich format similar to ELISA. 
For example, protein abundance in cells was determined by Haab et al. [60], using 115 antigen and 
antibody  reactions.  This  was  the  first  published  report  to  use  a  two-color  differential  labeling  of 
samples in a protein microarray. The microarray format is also convenient for standardizing the routine 
analysis of analytes present in screening assays, such as cytokines released by cell cultures [61]. An 
antibody-based  microarray  for  the  multiplexed  detection  of  cholera,  diphtheria,  staphylococcal 
enterotoxin  B,  tetanus  toxins,  anthrax  protective  antigen,  and  lethal  factor  was  reported  [62].  A 
competition assay between labeled and unlabeled toxins in serum was used to simultaneously detect all 
the toxins in the antibody microarray. In another report, a sandwich fluorescence immunoassay based 
on an antibody microarray format was developed for the capture and detection of E. coli O157.H7 
[63], and later to screen large number of food samples in a high-throughput manner to simultaneously 
detect E coli O157:H7 and Salmonella typhimurium [64].  
The major drawback of capture microarrays is that few well-defined and high-quality antibodies 
against microorganisms are available. Engineering antibody fragments is a potential alternate approach 
to  accelerate  the  development  of  antigen-capture  molecules.  Antibody  fragments  such  as  the  Fab Int. J. Mol. Sci. 2010, 11                       
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portion  of  IgG [65], phage display libraries  or  recombinant  single chain  variable fragment (scFv) 
containing  the  antigen-binding  motif  can  be  used  in  place  of  antibodies  in  protein  microarray 
development [66,67]. A decreased cross-reactivity was also observed with fragments as compared to 
full-length antibodies.  
8. Microarray Printing  
Thin-layered nitrocellulose or chemically modified 2-D surfaces (glass, silicon, gold, and polymer) 
are  generally  used  for  immobilization  of  microarrayed  proteins.  Buffer  additives  like  glycerol, 
polyethylene glycol, or sugars that prevent drying of the proteins and choice of buffers should be 
carefully selected to match the type of surfaces used for arraying. Alternatively, gel-based 3-D surfaces 
made  from  polyacrylamide  or  agarose  provide  a  hydrophilic  environment  [68].  Regardless  of  the 
printing  substrate  selected,  microarrayed  proteins  must  retain  functionality  and  stability  during 
preparation and use. Though it may not be possible to directly examine all elements of an array, it is 
important to include printing controls of interacting proteins that can be tested for functionality before 
use. There are several methods by which proteins are spotted onto substrates. The choice of technology 
used impacts spotting consistency, speed, spot diameter, and ease of use. In turn, the final spot quality 
required  for  printed  proteins  will  depend  on  the  method  of  detection.  Control  of  the  laboratory 
environment  to  maintain  constant  temperature,  humidity,  and  clean-room  conditions  will  vastly 
improve printing consistency. Printing with solid pins (for example Stealth Pin, Arrayit Corportion, 
Sunnyvale, CA, USA) relies on capillary forces to release spots on contact with the surface, resulting 
in 60–600 m diameter spots depending on buffer composition and pin diameter. Dip-pen lithography 
(DPN)  uses  atomic  force  microscopy  microcantilevers  to  deposit  spots  in  the  range  of  1–60  m 
diameter (Nano eNabler, Bioforce Nanosciences, Ames, IA, USA) and inkjet printers (for example 
Arrayjet, Roslin, Scotland) use piezoelectric elements to transfer the protein solution in the form of 
droplets to the target surface, resulting in spot diameters of 80–150 m. Both pin and inkjet spotting 
methods deposit a very small amount of protein, requiring highly concentrated samples. Unfortunately, 
highly concentrated samples may fail to adsorb completely on the surface and tend to spread during 
hydration. A new continuous flow microspotting method (Wasatch Microfluidics, Taylorsville, UT, 
USA) uses microfluidic channel networks to continuously circulate protein samples over a spot to 
achieve uniform and maximum protein adsorption [69]. This technique may be especially useful for 
dilute and crude protein sample arraying. 
9. Labeled Detection of Binding Events 
Fluorescence-based  labeling  of  probes  is  most  commonly  used  to  detect  binding  events,  due 
primarily to simplicity and sensitivity. Examples are amine-reactive dyes such as cyanines (Cy3 and 
Cy5) or labeling probes with biotin followed by detection with an avidin-fluorescent dye conjugate. 
CCD cameras or fluorescent slide scanners are used for detection of the labeled probes within defined 
grid areas. Sandwich immunoassay methods provide increased sensitivity and at the same time reduce 
non-specific binding, but their use is limited by the availability of paired antibodies. Using a rolling 
circle amplification (RCA) method can dramatically increase fluorescent signal intensity [70], thus 
increasing sensitivity in protein microarray detection methods. In this scheme, proteins are labeled Int. J. Mol. Sci. 2010, 11                       
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with  biotin  and recognized by  an antibody  conjugated with  a primer to which a circular DNA is 
hybridized. Fluorescently labeled oligonucleotides are used for elongation of DNA and detection. A 
universal RCA signal amplification scheme was used [71] for measuring cytokines in a multiplexed 
format.  A  total  of  75  cytokines  were  simultaneously  measured  on  an  antibody  microarray, 
demonstrating that even larger number of analytes can be measured by this technology. Thus, RCA is a 
powerful tool for improving the detection limits of protein microarrays by signal amplification.  
Current fluorescence-based detection in protein microarrays is limited to two to three independent 
probes because broad emission profiles exhibited by the dyes used for detection often overlap with 
each other and with the background fluorescence emitted by substrates, such as the commonly used 
nitrocellulose. Also, multiple excitation and emission channels are required to detect combinations of 
fluorescent markers. Quantum dot (QDs) nanoparticles are one alternative to fluorescent dyes. The 
QDs  are  semiconducting  fluorophores  that  are  extremely  bright,  resist  photobleaching,  and  have 
multiplexing capability. Each contains an inorganic fluorescent core, commonly CdSe, coated with a 
shell  of  another  semiconductor  such  as  CdS  or  ZnS.  The  most  important  property  of  QDs  with 
reference to protein microarray detection is that they absorb light at broad wavelengths, from UV to 
visible range and emit light at a very narrow bandwidth, in contrast to fluorescent dyes. Additionally, 
the  QD  surfaces  may  be  modified  with  suitable  chemistries  for  immobilizing  biomolecules. 
Streptavidin-coated QDs in a protein microarray format were used to detect six different cytokines at 
picomolar concentrations  [72], currently the practical  limit  for multiplexing with  QDs.  Additional 
multiplexing strategies have been previously described in detail [23]. 
Bead-based microarrays offer one solution to multiplexing. Most commercially available methods 
were developed by Luminex (xMAP platform). The xMAP technology is based on polymer beads 
incorporated with fluorescent dyes that produce unique signatures. These beads can be conjugated to 
different molecules to perform multiplexed assays. Up to 100 discrete interactions can be monitored 
simultaneously  using  this  technology  [73],  perhaps  extended  to  500  bead  sets  in  the  near  future. 
Antigens  or  peptides  have  been  attached  to  the  Luminex  beads  and  antibody  responses  to 
papillomavirus [74], Epstein-Barr virus [75,76], and Mycobacterium tuberculosis [77] were reported. 
Becton Dickinson (Franklin Lakes, NJ, USA) markets a cytometric bead array (CBA) system, which is 
another multiplexed bead-based assay that includes flow cytometry for cytokine, chemokine, mouse 
isotyping, and signaling molecule analysis.  
10. Label-Free Detection 
Label-free detection methods are used for real-time monitoring of binding events and to minimize 
artifacts caused by using labeled probes. SPR imaging technology is widely used in a microarray 
format for many applications. SPR is label-free, allows real-time monitoring, and has the additional 
ability to measure kinetics of the molecular interactions (Figure 1). SPR imaging was developed to 
simultaneously  measure  SPR  dip  changes  in  an  array  format,  recorded  with  a  CCD  camera.  
Grating-coupled (Flexchip, GE/Biacore, Piscataway, NJ, USA) and prism-coupled (SPRi-Plex, Horiba 
Scientific, Edison, NJ, USA, ProteOn XPR36, Bio-Rad, Hercules, CA, USA) SPRi systems are some 
examples of commercially available SPRi microarray systems. A model protein-protein interaction 
system was reported [78], consisting of the E6 protein of human papillomavirus complexing with the Int. J. Mol. Sci. 2010, 11                       
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proteins E6AP and p53 using a SPRi system. In another example, an array-based spectral SPR system 
was used for measuring antibody response to mumps virus infection [79]. In this system the reflected 
light from the array was collected into a fiber optic spectrometer for analysis. Our laboratory routinely 
uses SPRi microarrays to validate interactions that were detected during primary microarray screens 
from a fluorescent probe read-out. Because spot sizes must be large enough for resolution by the 
commonly  used  CCD  imaging,  practical  array  densities  are  currently  less  than  1000  independent 
immobilized probes. 
Additional  label-free  detection  methods  have  been  described.  Surface-enhanced  laser 
desorption/ionization  time  of  flight  mass  spectrometry  (SELDI-TOF-MS)  has  been  used  as  a  low 
throughput method for on-chip purification of proteins, ionization, and detection [80]. However, this 
approach was not very successful in identifying biomarkers in parasitic diseases, and most markers 
found  in  the  study  were  intact  host  proteins  [81,82].  Matrix-assisted  laser  desorption/ionization 
(MALDI)-MS in combination with 3-D gel surfaces [83] and silicon nanoporous nanovials [6] were 
also  used  for  biomarker  discovery.  The  MS-based  detection  systems  are  important  for  specific 
applications, but there have been only limited advancements in the development of microarray formats, 
currently  limiting  use  as  a  primary  screening  tool.  Nanowire-based  systems  detect  changes  in 
conductivity as a result of molecular binding [84,85]. It is possible to make an array of nanowires such 
that each nanowire is coated with a specific capture molecule. Gantelius et al. [86] reported a magnetic 
bead-based multiplexing format for the detection of auto-antibodies to 12 antigens, comparing the 
assay results to fluorescence-based detection system. Although the magnetic bead-based system was 
rapid, it was not sufficiently sensitive for routine use. 
11. Data Analysis 
Despite  the  rapid  progress  in  protein  microarray  development  standardized  methods  for  data 
handling  and  analysis  are  not  universally  accepted.  Fluorescence  scanners  made  by  different 
commercial  vendors  use  stand-alone  software  to  analyze  data,  while  assay  protocols  used  by 
investigators may vary widely. Hence, it is often difficult to compare studies reported by different 
groups, and there is a need to formulate standardized methods for protein microarray data handling and 
analysis. A number of reports have outlined ways to normalize protein microarray data, mainly for 
different approaches to  antibody microarrays.  These normalization methods  include concentration-
dependant  analysis [87,88], spiked internal standards [89], and algorithm-based [90], and all have 
significant  pros  and  cons.  Invitrogen/Life  Technologies  (Carlsbad,  CA,  USA)  developed  a  data 
analysis  package  (ProtoArray  Prospector)  specifically  designed  for  protein  antigen  microarrays, 
including a suite of statistical methods. BioArray software environment (BASE), a software package 
for microarray data management and analysis (http://base.thep.lu.se) developed by Lund University, 
Sweden, also addresses some of the issues we have outlined. However, it remains to be seen how 
rapidly standards will be adopted by the research community.  
12. Conclusions 
Antibodies are primary biomarkers of infection that are commonly used for diagnosis, measuring 
vaccine efficacy, and discovery of disease interventions. Protein microarrays are important tools for Int. J. Mol. Sci. 2010, 11                       
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measuring  these  complex  antigen-antibody  interactions  and  other  host-pathogen  interactions  at 
different stages of the disease. The major impediments to development of protein microarrays are the 
inherent complexity of proteins themselves, availability of well-characterized antibodies to infectious 
agents, and standardized statistical methods for analysis of data. However, we expect many of these 
issues  to  be  resolved  in  the  coming  years  as  these  tools  are  used  more  frequently  in  infectious  
disease research.  
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